A study found people who lost weight with the Type 2 diabetes drug Invokana (canagliflozin) got hungrier and ate more, leading to a weight loss plateau.
The study conducted by David Polidori and colleagues will publish in Obesity during Obesity Week 2016, which runs from Oct. 13 to Nov.
